Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Non Operating Income (2020 - 2025)

Tarsus Pharmaceuticals has reported Non Operating Income over the past 6 years, most recently at $6.7 million for Q4 2025.

  • Quarterly results put Non Operating Income at $6.7 million for Q4 2025, up 25055.56% from a year ago — trailing twelve months through Dec 2025 was $8.5 million (up 129.78% YoY), and the annual figure for FY2025 was $6.6 million, up 3308.74%.
  • Non Operating Income for Q4 2025 was $6.7 million at Tarsus Pharmaceuticals, up from $1.9 million in the prior quarter.
  • Over the last five years, Non Operating Income for TARS hit a ceiling of $6.7 million in Q4 2025 and a floor of -$4.4 million in Q4 2023.
  • Median Non Operating Income over the past 5 years was $9000.0 (2023), compared with a mean of $576650.0.
  • Biggest five-year swings in Non Operating Income: tumbled 3590.0% in 2021 and later skyrocketed 32450.0% in 2024.
  • Tarsus Pharmaceuticals' Non Operating Income stood at -$349000.0 in 2021, then surged by 366.76% to $931000.0 in 2022, then plummeted by 577.23% to -$4.4 million in 2023, then surged by 99.39% to -$27000.0 in 2024, then soared by 25055.56% to $6.7 million in 2025.
  • The last three reported values for Non Operating Income were $6.7 million (Q4 2025), $1.9 million (Q3 2025), and -$145000.0 (Q2 2025) per Business Quant data.